216 related articles for article (PubMed ID: 22724467)
1. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.
Gerotziafas GT; Galea V; Mbemba E; Sassi M; Roman MP; Khaterchi A; van Dreden P; Japcowitz M; Lotz JP; Bernaudin JF; Fareed J; Hatmi M; Elalamy I
Curr Vasc Pharmacol; 2014; 12(6):893-902. PubMed ID: 22724467
[TBL] [Abstract][Full Text] [Related]
2. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
3. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Sassi M; Chakroun T; Mbemba E; Van Dreden P; Elalamy I; Larsen AK; Gerotziafas GT
Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
5. Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Rousseau A; Van Dreden P; Mbemba E; Elalamy I; Larsen A; Gerotziafas GT
Thromb Res; 2015 Dec; 136(6):1273-9. PubMed ID: 26489727
[TBL] [Abstract][Full Text] [Related]
6. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the antithrombotic fingerprint of the branded and copies of the low-molecular-weight enoxaparin using thrombin generation assay.
Gerotziafas GT; Rouseau A; Mbemba E; Khartechi A; Van Dreden P; Walenga J; Fareed J; Elalamy I
Clin Appl Thromb Hemost; 2015 Nov; 21(8):697-704. PubMed ID: 26023170
[TBL] [Abstract][Full Text] [Related]
8. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
9. OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Gerotziafas GT; Rousseau A; van Dreden P; Mbemba E; Gkalea V; Khaterchi A; Larsen A; Elalamy I
Thromb Res; 2016 Apr; 140 Suppl 1():S169. PubMed ID: 27161675
[TBL] [Abstract][Full Text] [Related]
10. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
11. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
12. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.
Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J
Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG
Curr Opin Pulm Med; 2002 Sep; 8(5):398-404. PubMed ID: 12172443
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of dalteparin on thrombin generation in canine plasma.
Gara-Boivin C; Del Castillo JRE; Dunn ME; Bédard C
Vet Clin Pathol; 2017 Sep; 46(3):442-450. PubMed ID: 28605123
[TBL] [Abstract][Full Text] [Related]
16. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
Samama MM; Bara L; Gerotziafas GT
Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
[TBL] [Abstract][Full Text] [Related]
20. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
